Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple ...

Vertex Pharmaceuticals is downgraded to Hold ahead of Q4 earnings due to underwhelming growth from key new drugs. Click for ...

Venture capital firm Vertex Ventures, backed by Singapore state investor Temasek, is set to raise nearly $500 million for a new fund that will invest in efforts to step up China's domestic tech ...

In early February 2026, WuXi Biologics announced a license and research service agreement granting Vertex Pharmaceuticals exclusive global rights to develop and commercialize a preclinical trispecific ...

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are covering the ...